TRT side effects: separating real risks from fear-based claims

What's this video probably claiming?

Based on the caption and creator handle (@biblehealthbook, which signals a religiously or morally inflected skepticism of medical interventions), this video appears to frame testosterone replacement therapy as broadly harmful, possibly reckless, and something men should avoid. The listed side effects, acne, fluid retention, gynecomastia, testicular shrinkage, infertility, elevated red blood cell count, and sleep apnea, are real phenomena associated with TRT. But the framing of TRT as "a terrible idea for health" suggests the creator is presenting these risks without the counterweight of clinical benefit data, prevalence rates, or the established risks of untreated hypogonadism. That framing is where the video likely goes from informative to misleading. The question is not whether these side effects exist. They do. The question is how often they occur, at what doses, in which populations, and whether the benefit-risk calculus still favors treatment in men with confirmed low testosterone.

What does the science actually show?

The side effects listed in the caption are real, but frequency and severity depend heavily on protocol, monitoring, and patient selection. Polycythemia (elevated red blood cell count) occurs in roughly 5 to 10 percent of men on injectable testosterone, according to Bhasin et al. (2010, New England Journal of Medicine), and is manageable with dose adjustments or therapeutic phlebotomy. Gynecomastia is more common with supraphysiologic dosing and can be mitigated by aromatase inhibitor use where clinically indicated. Testicular atrophy and infertility are real consequences of exogenous testosterone suppressing LH and FSH, but fertility can often be preserved with co-administration of human chorionic gonadotropin (hCG), as reviewed by Ramasamy et al. (2015, Fertility and Sterility). The Testosterone Trials, a coordinated set of seven trials published in NEJM between 2016 and 2018, found significant improvements in sexual function, bone density, and mood in older hypogonadal men with carefully monitored therapy. Side effects were present but manageable in a supervised clinical setting.

Where does the social media noise diverge from clinical reality?

The gap between TikTok TRT discourse and actual clinical practice is significant. Social media tends to flatten nuance. Either TRT is a miracle cure for every man over 30 (the "optimization" bro content), or it is a dangerous hormone manipulation that causes cancer, heart attacks, and infertility (the fear-based content). This video appears to lean into the second camp. What gets lost is that TRT is an FDA-approved treatment for hypogonadism, a diagnosable condition affecting an estimated 2 to 6 percent of men, per Mulligan et al. (2006, International Journal of Clinical Practice). The cardiovascular risk narrative is worth addressing specifically. Early observational studies raised red flags, but a 2023 randomized controlled trial by Lincoff et al. in the New England Journal of Medicine (the TRAVERSE trial, 5,246 participants) found no significant increase in major cardiovascular events in middle-aged and older men with hypogonadism and elevated cardiovascular risk treated with testosterone gel over a median follow-up of 33 months. That is not a small study. That is not easy to dismiss.

What should you actually know?

TRT is not appropriate for every man who feels tired or wants to build muscle. That distinction matters. But for men with clinically confirmed hypogonadism, defined by consistently low serum testosterone (generally below 300 ng/dL on two morning measurements) combined with symptoms, the evidence supports treatment under physician supervision. Untreated hypogonadism carries its own health risks, including reduced bone mineral density, increased visceral fat, insulin resistance, and depression, as documented by Traish et al. (2014, Journal of Andrology). The side effects listed in this video's caption are real and worth knowing about, but presenting them without context, without prevalence data, without the distinction between supervised medical therapy and unsupervised use, turns a partial truth into a misleading picture. If you are considering TRT, the actual conversation to have is with a physician who orders the right labs, monitors hematocrit, PSA, and estradiol, and adjusts protocol based on your individual response. A 60-second TikTok video is not that conversation.